TRP Ca2+ Channels in the Skin
皮肤中的 TRP Ca2 通道
基本信息
- 批准号:9117392
- 负责人:
- 金额:$ 33.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAnimal ModelAnimalsBiochemicalBiological AssayBreastCarcinomaCellsClinicalClinical TrialsColonColorectal CancerComplexCutaneousDevelopmentDrug ToleranceElectrophysiology (science)Epidermal Growth Factor ReceptorEpidermisEpithelialEpithelial Cell ProliferationEpithelial CellsExhibitsFamilyFeedbackGeneticGoalsGrowthHairHumanImageIn VitroInbred HRS MiceInflammation MediatorsIon ChannelMalignant NeoplasmsMediatingMolecularMonoclonal AntibodiesMusMutationNude MiceOncogenesOncogenicOrganOutcomePainPaperPapillomaPhenotypePredispositionPreventionProstateProtocols documentationPublishingReportingResearchResistanceRoleSignal TransductionSkinSkin CarcinogenesisSkin NeoplasmsSkin PapillomaSquamous cell carcinomaStagingTestingTherapeuticTissuesTransgenic MiceTumor PromotionTyrosine Kinase InhibitorUltraviolet B RadiationUp-Regulationbasecancer therapycarcinogenesischemical carcinogenesiscytokinegain of functionhigh riskin vivo Modelinhibitor/antagonistinsightirradiationkeratinocytekillingsneoplastic cellnew therapeutic targetnovelnovel strategiesnovel therapeutic interventionoverexpressionras Oncogenerisk variantsmall moleculesmall molecule inhibitortumortumor progressiontumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The majority of human cancers arise in the epithelial tissues of organs such as skin and colon. Uncontrolled proliferation of epithelial cells is often caused by aberrant signaling of growth factors and cytokines. A commonality among many epithelial tumors is an elevation of EGFR signaling. In fact, anti-EGFR strategies (EGFR monoclonal antibodies and small molecule tyrosine-kinase inhibitors; TKIs) are currently among the most common anti-cancer therapies. However, most anti-EGFR agents cause adverse side effects and are only partially effective due to quickly developed drug tolerance. We seek an alternative and novel strategy to treat EGFR-dependent carcinomas. Our proposal seeks to build on our recently made, and unexpected, discovery that TRPV3, a Ca2+ channel expressed in many epithelial tissues, including skin, colon, and prostate, is a key regulator of EGFR signaling. TRPV3 forms a signaling complex with TGF-a/EGFR; activation of EGFR leads to increased TRPV3 channel activity, which in turn stimulates TGF-a release mediated by ADAM-family sheddase. At the animal level, TRPV3-deficient mice exhibit similar hair/skin phenotypes as mice with defective TGF-a/EGFR signaling. Thus, TRPV3 could be a novel therapeutic target for skin and other epithelial cancers. Although ion channels are not known targets for cancer treatment, TRPV3 is recently reported to be a high-risk gene in colorectal cancer. Moreover, small molecule TRPV3 inhibitors are in clinical trials for reducing pain induced by inflammatory mediators, many of which are also potent tumor-promoting agents. Therefore, we specifically hypothesize that TRPV3 channel up-regulation in keratinocytes is a maladaption that accelerates skin tumorigenesis. Using animal models of skin carcinogenesis, we will investigate whether TRPV3 expression and channel function are up-regulated during epithelial malignancy, and whether genetic and pharmacological inactivation of TRPV3 may delay promotion/progression of epithelial tumors. Our first aim is to investigate TRPV3 expression/function during keratinocyte transformation and skin tumorigenesis. Our second aim is to study the roles of TRPV3 in the development of skin tumors using mice with genetically modified expression of TRPV3. Our third aim is to investigate the roles of TRPV3 in the development of skin tumors using TRPV3-specific small molecule inhibitors. Overall, the close interaction of TRPV3 and EGFR signaling on normal epidermis and the well-demonstrated role of EGFR signaling in cancer suggest a role of TRPV3 in epithelial tumorigenesis. The goal of this proposed research is to lay the groundwork necessary to develop new therapeutic strategies for skin and other epithelial cancers.
描述(由申请人提供):大多数人类癌症发生在器官的上皮组织,如皮肤和结肠。上皮细胞不受控制的增殖通常是由生长因子和细胞因子的异常信号引起的。许多上皮性肿瘤的一个共性是EGFR信号的升高。事实上,抗EGFR策略(EGFR单克隆抗体和小分子酪氨酸激酶抑制剂;TKIs)是目前最常见的抗癌疗法之一。然而,大多数抗egfr药物会产生不良副作用,并且由于迅速产生耐药性,只能部分有效。我们寻求一种新的替代策略来治疗egfr依赖性癌。我们的建议旨在建立在我们最近取得的和意想不到的发现之上,即TRPV3,一个在许多上皮组织中表达的Ca2+通道,包括皮肤,结肠和前列腺,是EGFR信号的关键调节剂。TRPV3与TGF-a/EGFR形成信号复合物;EGFR的激活导致TRPV3通道活性增加,进而刺激由adam家族脱落酶介导的TGF-a释放。在动物水平上,trpv3缺陷小鼠表现出与TGF-a/EGFR信号缺陷小鼠相似的毛发/皮肤表型。因此,TRPV3可能成为皮肤和其他上皮癌的新治疗靶点。虽然离子通道不是癌症治疗的已知靶点,但最近报道TRPV3是结直肠癌的高危基因。此外,小分子TRPV3抑制剂正在临床试验中,用于减轻炎症介质引起的疼痛,其中许多炎症介质也是有效的肿瘤促进剂。因此,我们特别假设,角质形成细胞中的TRPV3通道上调是一种加速皮肤肿瘤发生的不适应。通过皮肤癌变动物模型,我们将研究在上皮恶性肿瘤过程中TRPV3的表达和通道功能是否上调,以及TRPV3基因和药理学失活是否可能延缓上皮肿瘤的促进/进展。我们的第一个目的是研究TRPV3在角质细胞转化和皮肤肿瘤发生过程中的表达/功能。我们的第二个目标是使用转基因TRPV3表达的小鼠研究TRPV3在皮肤肿瘤发展中的作用。我们的第三个目标是利用TRPV3特异性小分子抑制剂研究TRPV3在皮肤肿瘤发展中的作用。总的来说,TRPV3和EGFR信号在正常表皮上的密切相互作用以及EGFR信号在癌症中的良好作用表明TRPV3在上皮肿瘤发生中的作用。这项研究的目的是为开发新的皮肤和其他上皮性癌症的治疗策略奠定必要的基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Haoxing Xu其他文献
Haoxing Xu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Haoxing Xu', 18)}}的其他基金
Kinetic High Throughput Screening for Agonists and Inhibitors of the TRPML1 Ion c
TRPML1 离子 c 激动剂和抑制剂的动力学高通量筛选
- 批准号:
8262514 - 财政年份:2011
- 资助金额:
$ 33.8万 - 项目类别:
High Throughput Screening for Modulators of the TRPML1 Ion Channel
TRPML1 离子通道调制器的高通量筛选
- 批准号:
8402809 - 财政年份:2011
- 资助金额:
$ 33.8万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 33.8万 - 项目类别:
Grant-in-Aid for Early-Career Scientists